the growth of cancer cells. It may also stop the patient''s immune system from rejecting the
donor''s stem cells. Also, monoclonal antibodies, such as rituximab, can find cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells. The donated stem cells may replace the patient''s immune cells and help destroy any
remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a
donor can also make an immune response against the body''s normal cells. Giving tacrolimus,
sirolimus, and methotrexate after the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well donor stem cell transplant works in
treating patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.